DelveInsight’s ‘Postoperative Pain- Market Insight, Epidemiology and Market Forecast—2032’ report deliver an in-depth understanding of the Postoperative Pain, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Postoperative Pain market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Postoperative Pain symptoms market size from 2019 to 2032 segmented by seven major markets. The report also covers current Postoperative Pain symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geographies Covered
The United States
The EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan
Study Period: 2019-2032
Postoperative Pain Understanding and Treatment Algorithm
Postoperative Pain Overview
Postoperative Pain is an anticipated and temporary increase in background pain that occurs following surgical procedures. It is a type of pain that typically lasts less than a few days to months or pain directly related to soft tissue damage such as a sprained ankle or a paper cut. The pain is of short duration, but it gradually resolves as the injured tissues heal.
The intensity, quality, and duration of postoperative pain are affected mainly by location, type, and duration of the surgical procedure; type and extent of the incision and surgical trauma; the physical and mental state of the patient, including the patient’s approach to pain; preoperative psychological and pharmacological preparation; type of anesthesia; pain management before and after the surgical procedure; incidence of surgical complications; and quality of postoperative care.
For efficient treatment, it needs to be properly diagnosed, measured, and documented. Only by this procedure, optimal analgesia may be achieved, a mild and tolerable sensation of pressure in the surgical wound with minimal adverse effects. Proper diagnosis of the type and intensity of pain is crucial for an adequate and targeted treatment of acute pain. It requires a highly professional approach in terms of expertise, psychology, and ethics.
Specific evaluation of pain includes the location of the pain and its radiation, quality of the pain (dull, sharp, throbbing, shooting, burning, etc.), duration of the pain (constant, intermittent, paroxysmal), causative factors (movement, sitting position, cough, etc., the intensity of the pain at rest or during movement), accompanying symptoms, quality of sleep, assessment of the patient’s expectations, personal approach to pain, stress, and pain coping strategies, analgesic therapy preferences.
Postoperative Pain Diagnosis and Treatment
It covers the details of conventional and current medical therapies and diagnosis available in the Postoperative Pain market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The DelveInsight Postoperative Pain market report gives a thorough understanding of Postoperative Pain symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Postoperative Pain algorithms and treatment guidelines in the US, Europe, and Japan.
Postoperative Pain Epidemiology
The epidemiology division’s Postoperative Pain symptoms provide insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Postoperative Pain epidemiology segmented as the Total number of surgical procedures, Total number of Incident cases of Postoperative Pain, Severity-specific incident cases of Postoperative Pain. The report includes the Postoperative Pain scenario in the 7MM, covering the United States, the EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise- Postoperative Pain Epidemiology
The epidemiology segment also provides the Postoperative Pain epidemiology data and findings across the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total 7MM incident population of Postoperative Pain were 66,833,180 cases in 2022.
Postoperative Pain Drug Chapters
The drug chapter segment of the Postoperative Pain report encloses the detailed analysis of Postoperative Pain marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Postoperative Pain clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Products detail in the report…
Postoperative Pain Emerging Drugs
CR845/Difelikefalin (Cara Therapeutics)
Cara Therapeutics is developing the first peripherally acting kappa opioid receptor agonist (KORA) called CR845. The drug is a potent peripheral kappa-opioid receptor agonist with high selectivity over other opioid receptors in the body. The degree of kappa receptor selectivity displayed by CR845 is the best-in-class compared to all other previously developed compounds for this therapeutic target.
The drug is designed to produce pain relief by specifically stimulating kappa, rather than mu, opioid receptors. Moreover, the drug is designed with specific chemical characteristics to restrict its entry into the CNS and further limit the mechanism of action to kappa opioid receptors in the peripheral nervous system, consisting of the nerves outside the brain and spinal cord.
Products detail in the report…
Postoperative Pain Market Outlook
The Postoperative Pain market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Postoperative Pain market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
This segment gives a thorough detail of Postoperative Pain market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Postoperative Pain market in 7MM is expected to change in the study period 2019-2032.
Key Findings
This section includes a glimpse of the Postoperative Pain market in 7MM. The market size of Postoperative Pain in the seven major markets was found to be USD 2,799 million in 2022.
The United States Market Outlook
This section provides a total of Postoperative Pain market size and market size by therapies in the United States.
The United States accounts for higher Postoperative Pain market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
EU-5 Countries: Market Outlook
The total Postoperative Pain market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total Postoperative Pain market size and market size by therapies in Japan are also mentioned.
Postoperative Pain Drugs Uptake
This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2019-2032. The analysis covers Postoperative Pain market uptake by drugs, patient uptake by therapies, and drug sales.
This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake in making financial and regulatory decisions.
Postoperative Pain Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Postoperative Pain key players involved in developing targeted therapeutics.
Major players CR845/Difelikefalin (Cara Therapeutics), VVZ-149 Injections, and others are being assessed as potential therapies to be available in the market in the coming future.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Postoperative Pain emerging therapies.
KOL Views
To keep up with current market trends, we take KOLs and SME’s opinion working on Postoperative Pain domain through primary research to fill the data gaps and validate our secondary research. Their opinions help understand and validate current and emerging therapy treatment patterns or Postoperative Pain market trends. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.
Competitive Intelligence Analysis
We perform a Competitive and Market Intelligence analysis of the Postoperative Pain Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
The report covers the descriptive overview of Postoperative Pain explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
Comprehensive insight has been provided into the Postoperative Pain epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Postoperative Pain provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Postoperative Pain market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies by understanding trends shaping and driving the global Postoperative Pain market
Report Highlights
In the coming years, Postoperative Pain market is set to change due to the rising awareness of the disease, resistant to the current antibiotic regime, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence Postoperative Pain R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
Major players are involved in developing therapies for Postoperative Pain. The launch of emerging therapies will significantly impact the Postoperative Pain market
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Postoperative Pain
Our in-depth analysis of the pipeline assets across different stages of development (Phase II and Phase III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Postoperative Pain Report Insights
Patient Population
Therapeutic Approaches
Postoperative Pain Pipeline Analysis
Postoperative Pain Market Size and Trends
Market Opportunities
Impact of upcoming Therapies
Postoperative Pain Report Key Strengths
11 Years Forecast
7MM Coverage
Postoperative Pain Epidemiology Segmentation
Key Cross Competition
Highly Analyzed Market
Drugs Uptake
Postoperative Pain Report Assessment
Current Treatment Practices
Unmet Needs
Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers
Key Questions
Market Insights:
What was the Postoperative Pain Market share (%) distribution in 2022, and how would it look in 2032?
What would be the Postoperative Pain total market Size as well as market Size by therapies across the 7MM during the forecast period (2021–2032)?
What are the market’s key findings across 7MM, and which country will have the largest Postoperative Pain market Size during the forecast period (2021–2032)?
At what CAGR, the Postoperative Pain market is expected to grow by 7MM during the forecast period (2021–2032)?
What would be the Postoperative Pain market outlook across the 7MM during the forecast period (2021–2032)?
What would be the Postoperative Pain market growth till 2032, and what will be the resultant market Size in the year 2032?
How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
What are the disease risk, burden, and unmet needs of Postoperative Pain?
What is the historical Postoperative Pain patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of Postoperative Pain in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What will be the growth opportunities in the 7MM concerning the patient population about Postoperative Pain?
Out of all 7MM countries, which country would have the highest incident Postoperative Pain population during the forecast period (2021–2032)?
At what CAGR is the population expected to grow by 7MM during the forecast period (2021–2032)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
What are the current options for the treatment of Postoperative Pain?
What are the current treatment guidelines for treating Postoperative Pain in the USA, Europe, and Japan?
What are the Postoperative Pain marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
How many companies are developing therapies for the treatment of Postoperative Pain?
How many therapies are developed by each company for the treatment of Postoperative Pain?
How many emerging therapies are in the mid-stage and late development stages to treat Postoperative Pain?
What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Postoperative Pain therapies?
What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Postoperative Pain and their status?
What are the key designations that have been granted for the emerging therapies for Postoperative Pain?
What are the global historical and forecasted markets of Postoperative Pain?
Reasons to buy
The report will help in developing business strategies by understanding trends shaping and driving the Postoperative Pain market
To understand the future market competition in the Postoperative Pain market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Postoperative Pain in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Postoperative Pain market
To understand the future market competition in the Postoperative Pain market
- 1. Report Introduction
- 2. Postoperative Pain Market Overview at a Glance
- 2.1. Market Share (%) Distribution of Postoperative Pain in 2019
- 2.2. Market Share (%) Distribution of Postoperative Pain in 2032
- 3. Postoperative Pain Market: Future Perspective
- 4. Executive Summary of Postoperative Pain
- 5. Disease Background and Overview
- 5.1. Introduction
- 5.2. Transition from Acute to Chronic Pain
- 5.2.1. Elective or Planned Procedures
- 5.2.2. Common Types of Acute Postoperative Pains
- 5.3. Pathophysiology of Acute Pain
- 5.3.1. Formation of reflexes in postoperative pain
- 5.3.1.1. Segmental reflexes
- 5.3.1.2. Suprasegmental reflexes
- 5.3.1.3. Cortical responses
- 5.3.2. Negative effects of postoperative pain on various organ systems
- 5.3.2.1. Changes in respiratory functions
- 5.3.2.2. Cardiovascular changes
- 5.3.2.3. Gastrointestinal and urinary changes
- 5.3.2.4. Neuroendocrine and metabolic changes
- 5.3.3. Psychological effects of postoperative pain
- 5.3.4. Late effects of insufficient postoperative analgesia
- 5.3.5. Chronic postoperative pain
- 5.4. Factors affecting postoperative pain
- 5.5. Diagnosis of Postoperative Pain
- 5.5.1. Medical history, physical examination, and specific evaluation of pain
- 5.5.2. Measuring pain
- 5.5.3. Various Grading Scales used for Diagnosis of Acute Pain
- 5.5.3.1. Visual Analogue Scale
- 5.5.3.2. Verbal Rating Scale
- 5.5.3.3. Graded Chronic Pain Scale (GCPS)
- 5.5.3.4. Numeric Rating Scale (NRS)
- 5.5.4. Verbal methods of pain assessment
- 5.5.5. Multidimensional methods of pain assessment
- 5.5.6. Nonverbal methods of pain assessment
- 5.5.7. Diagnostic Algorithm
- 5.5.8. Guidelines
- 5.5.8.1. Guidelines on the Management of Postoperative Pain
- 5.5.8.2. Goals and Elements of the Initial Assessment
- 5.6. Treatment
- 5.6.1. Pharmacological Therapies
- 5.6.2. Multimodal analgesia
- 5.6.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- 5.6.3.1. Nonselective COX inhibitors
- 5.6.3.2. Preferential COX-2 inhibitors
- 5.6.3.3. Selective COX-2 inhibitors – coxibs
- 5.6.4. Opioids
- 5.6.4.1. Weak opioid analgesics
- 5.6.4.2. Strong opioid analgesics
- 5.6.5. Non-opioid analgesics
- 5.6.5.1. Paracetamol (acetaminophen)
- 5.6.5.2. Metamizole
- 5.6.6. Procedure-specific analgesia
- 5.6.6.1. Discharge planning
- 5.6.7. Regional anesthesia
- 5.6.8. Non-Pharmacological Methods to Treat Acute Pain
- 5.6.8.1. Cognitive dysfunction
- 5.6.8.2. Herbal medicine
- 5.6.8.3. Homeopathy
- 5.6.8.4. Meditation
- 5.6.9. Physical methods
- 5.6.9.1. Cold
- 5.6.9.2. Heat
- 5.6.9.3. Transcutaneous electrical nerve stimulation (TENS) in Acute Post-Operative Pain
- 5.6.9.4. Acupuncture
- 5.6.9.5. Hypnosis
- 5.6.9.6. Immobilization
- 5.6.9.7. Massage
- 5.6.10. Intravenous Patient-Controlled Analgesia (PCA)
- 5.6.10.1. Patient-Controlled Epidural Analgesia
- 5.6.11. Nerve Blocks
- 5.6.12. Pediatric Pain Management
- 5.6.13. Treatment Algorithm for Acute Postoperative Pain
- 5.6.14. Guidelines for Acute Pain
- 5.6.14.1. Recent advances in acute pain management: understanding the mechanisms of acute pain, the prescription of opioids, and the role of multimodal pain therapy (2017)
- 5.6.14.2. Management of Postoperative Pain: A Clinical Practice Guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia, Executive Committee, and Administrative Council (2017)
- 5.6.15. Recommendations for Pre- and Intra-operative Pain Management by The European Society of Regional Anaesthesia and Pain Therapy
- 6. Epidemiology and Patient Population
- 6.1. Key Findings
- 6.2. Methodology of Epidemiology
- 6.3. Total number of Incident cases of Postoperative Pain in the 7MM
- 6.4. Epidemiology of Postoperative Pain
- 6.5. United States
- 6.5.1. Total number of surgical procedures in the US
- 6.5.2. Total number of Incident cases of Postoperative Pain in the US
- 6.5.3. Severity-specific incident cases of Postoperative Pain in the US
- 6.6. EU5
- 6.6.1. Germany
- 6.6.1.1. Total number of surgical procedures in Germany
- 6.6.1.2. Total number of Incident cases of Postoperative Pain in Germany
- 6.6.1.3. Severity-specific incident cases of Postoperative Pain in Germany
- 6.6.2. France
- 6.6.2.1. Total number of surgical procedures in France
- 6.6.2.2. Total number of Incident cases of Postoperative Pain in France
- 6.6.2.3. Severity-specific incident cases of Postoperative Pain in France
- 6.6.3. Italy
- 6.6.3.1. Total number of surgical procedures in Italy
- 6.6.3.2. Total number of Incident cases of Postoperative Pain in Italy
- 6.6.3.3. Severity-specific incident cases of Postoperative Pain in Italy
- 6.6.4. Spain
- 6.6.4.1. Total number of surgical procedures in Spain
- 6.6.4.2. Total number of Incident cases of Postoperative Pain in Spain
- 6.6.4.3. Severity-specific incident cases of Postoperative Pain in Spain
- 6.6.5. United Kingdom
- 6.6.5.1. Total number of surgical procedures in the UK
- 6.6.5.2. Total number of Incident cases of Postoperative Pain in the UK
- 6.6.5.3. Severity-specific incident cases of Postoperative Pain in the UK
- 6.7. Japan
- 6.7.1. Total number of surgical procedures in Japan
- 6.7.2. Total number of Incident cases of Postoperative Pain in Japan
- 6.7.3. Severity-specific incident cases of Postoperative Pain in Japan
- 7. Patient Journey
- 8. Marketed Drugs
- 8.1. Marketed Drugs Key-cross Competition
- 8.2. Enanplus/Takudex (Dexketoprofen/Tramadol): Menarini Group/Guidotti Farma
- 8.2.1. Product Description
- 8.2.2. Regulatory Milestones
- 8.2.3. Other Developmental activities
- 8.2.4. Clinical Development
- 8.2.5. Clinical Trials Information
- 8.2.6. Safety and Efficacy
- 8.2.7. Product Profile
- 8.3. Dsuvia/Dzuveo (Sufentanil): AcelRx Pharmaceuticals
- 8.3.1. Product Description
- 8.3.2. Regulatory Milestones
- 8.3.3. Other Developmental activities
- 8.3.4. Clinical Development
- 8.3.5. Clinical Trials Information
- 8.3.6. Safety and Efficacy
- 8.3.7. Product Profile
- 8.4. Zalviso: AcelRx Pharmaceuticals
- 8.4.1. Product Description
- 8.4.2. Regulatory Milestones
- 8.4.3. Other Developmental activities
- 8.4.4. Clinical Development
- 8.4.5. Clinical Trials Information
- 8.4.6. Safety and Efficacy
- 8.4.7. Product Profile
- 8.5. Olinvyk (Olinvo) (oliceridine): Trevena, Inc.
- 8.5.1. Product Description
- 8.5.2. Regulatory Milestones
- 8.5.3. Other Development Activities
- 8.5.4. Clinical Development
- 8.5.5. Clinical Trials Information
- 8.5.6. Safety and Efficacy
- 8.5.7. Product Profile
- 8.6. Zynrelef (HTX-011): Heron Therapeutics
- 8.6.1. Product Description
- 8.6.2. Regulatory Milestones
- 8.6.3. Other Developmental Activities
- 8.6.4. Clinical Development
- 8.6.5. Clinical Trials Information
- 8.6.6. Safety and Efficacy
- 8.6.7. Product Profile
- 8.7. Xaracoll: Innocoll Pharmaceuticals
- 8.7.1. Product Description
- 8.7.2. Regulatory Milestones
- 8.7.3. Other Developmental activities
- 8.7.4. Clinical Development
- 8.7.5. Clinical Trials Information
- 8.7.6. Safety and Efficacy
- 8.7.7. Product Profile
- 8.8. Posimir (bupivacaine solution): DURECT Corporation
- 8.8.1. Product Description
- 8.8.2. Regulatory Milestones
- 8.8.3. Other Developmental activities
- 8.8.4. Clinical Development
- 8.8.5. Clinical Trials Information
- 8.8.6. Safety and Efficacy
- 8.8.7. Product Profile
- 8.9. Exparel: Pacira Pharmaceuticals
- 8.9.1. Product Description
- 8.9.2. Regulatory Milestones
- 8.9.3. Other Developmental activities
- 8.9.4. Clinical Development
- 8.9.5. Clinical Trials Information
- 8.9.6. Safety and Efficacy
- 8.9.7. Product Profile
- 8.10. Anjeso: Baudax Bio
- 8.10.1. Product Description
- 8.10.2. Regulatory Milestones
- 8.10.3. Other Development Activities
- 8.10.4. Clinical Development
- 8.10.5. Clinical Trials Information
- 8.10.6. Safety and Efficacy
- 8.10.7. Product Profile
- 8.11. Prolensa (bromfenac ophthalmic solution) 0.07%: Bausch & Lomb
- 8.11.1. Product Description
- 8.11.2. Regulatory Milestones
- 8.11.3. Clinical Development
- 8.11.4. Clinical Trials Information
- 8.11.5. Safety and Efficacy
- 8.11.6. Product Profile
- 8.12. Dextenza: Ocular Therapeutix
- 8.12.1. Product Description
- 8.12.2. Regulatory Milestones
- 8.12.3. Other Developmental activities
- 8.12.4. Clinical Development
- 8.12.5. Clinical Trials Information
- 8.12.6. Safety and Efficacy
- 8.12.7. Product Profile
- 8.13. Inveltys: Kala Pharmaceuticals, Inc.
- 8.13.1. Product Description
- 8.13.2. Regulatory Milestones
- 8.13.3. Other Developmental activities
- 8.13.4. Clinical Development
- 8.13.5. Clinical Trials Information
- 8.13.6. Safety and Efficacy
- 8.13.7. Product Profile
- 8.14. Penthrox: Medical Developments International Ltd (MVP)
- 8.14.1. Product Description
- 8.14.2. Regulatory Milestones
- 8.14.3. Other Developmental activities
- 8.14.4. Clinical Development
- 8.14.5. Clinical Trials Information
- 8.14.6. Safety and Efficacy
- 8.14.7. Product Profile
- 8.15. Lotemax SM (loteprednol etabonate ophthalmic gel): Bausch & Lomb
- 8.15.1. Product Description
- 8.15.2. Regulatory Milestones
- 8.15.3. Safety and Efficacy
- 8.15.4. Product Profile
- 8.16. Maxigesic: Hyloris Pharmaceuticals/AFT Pharmaceuticals
- 8.16.1. Product Description
- 8.16.2. Regulatory Milestone
- 8.16.3. Other Developmental Activities
- 8.16.4. Clinical Development
- 8.16.5. Clinical Trials Information
- 8.16.6. Safety and Efficacy
- 8.16.7. Product Profile
- 9. Emerging Drugs
- 9.1. Key Cross Competition
- 9.2. CR845/Difelikefalin: Cara Therapeutics
- 9.2.1. Product Description
- 9.2.2. Other Developmental Activities
- 9.2.3. Clinical Development
- 9.2.4. Clinical Trials Information
- 9.2.5. Safety and Efficacy
- 9.2.6. Product Profile
- 9.3. VVZ-149 Injections: Vivozon, Inc.
- 9.3.1. Product Description
- 9.3.2. Other Developmental Activities
- 9.3.3. Clinical Development
- 9.3.4. Clinical Trials Information
- 9.3.5. Safety and Efficacy
- 9.3.6. Product Profile
- 9.4. Tramadol IV: Avenue Therapeutics, Inc.
- 9.4.1. Product Description
- 9.4.2. Other Developmental Activities
- 9.4.3. Clinical Development
- 9.4.4. Clinical Trials Information
- 9.4.5. Safety and Efficacy
- 9.4.6. Product Profile
- 9.5. F14 (sustained-release celecoxib)/mdc-CWM (Celecoxib): Arthritis Innovation Corporation/MedinCell
- 9.5.1. Product Description
- 9.5.2. Other Developmental Activities
- 9.5.3. Clinical Development
- 9.5.4. Clinical Trials Information
- 9.5.5. Safety and Efficacy
- 9.5.6. Product Profile
- 9.6. Nefopam hydrochloride and paracetamol: Unither Pharmaceuticals
- 9.6.1. Product Description
- 9.6.2. Clinical Development
- 9.6.3. Clinical Trials Information
- 9.6.4. Product Profile
- 9.7. Co-crystal E-58425 (Tramadol/Celecoxib): Esteve Pharmaceuticals
- 9.7.1. Product Description
- 9.7.2. Other Developmental Activities
- 9.7.3. Clinical Development
- 9.7.4. Clinical Trials Information
- 9.7.5. Safety and Efficacy
- 9.7.6. Product Profile
- 9.8. APP13007: Formosa Pharmaceuticals
- 9.8.1. Drug Description
- 9.8.2. Regulatory Milestones
- 9.8.3. Clinical Development
- 9.8.4. Clinical Trials Information
- 9.8.5. Safety and Efficacy
- 9.8.6. Product Profile
- 9.9. NTM-001 (Ketorolac Pre-Mixed Bag): Neumentum Pharmaceuticals
- 9.9.1. Product Description
- 9.9.2. Other Developmental Activities
- 9.9.3. Clinical Developmental Activities
- 9.9.4. Safety and Efficacy
- 9.9.5. Product Profile
- 9.10. ACP-044: Acadia Pharmaceuticals Inc.
- 9.10.1. Product Description
- 9.10.2. Other Developmental Activities
- 9.10.3. Clinical Development
- 9.10.4. Clinical Trials Information
- 9.10.5. Product Profile
- 9.11. NVK-009 (Pregabalin and Acetaminophen): Nevakar, Inc.
- 9.11.1. Product Description
- 9.11.2. Clinical Development
- 9.11.3. Clinical Trials Information
- 9.11.4. Product Profile
- 9.12. TLC590: Taiwan Liposome Company (TLC)
- 9.12.1. Product Description
- 9.12.2. Other Developmental Activities
- 9.12.3. Clinical Development
- 9.12.4. Clinical Trials Information
- 9.12.5. Safety and Efficacy
- 9.12.6. Product Profile
- 9.13. MR-107A-01: Viatris Inc. (formerly known as Mylan Inc.)
- 9.13.1. Product Description
- 9.13.2. Other Developmental Activities
- 9.13.3. Clinical Development
- 9.13.4. Clinical Trials Information
- 9.13.5. Product Profile
- 9.14. TPU-006 (Dexmedetomidine Transdermal System (DMTS)): Teikoku Pharma USA, Inc.
- 9.14.1. Product Description
- 9.14.2. Other Developmental Activities
- 9.14.3. Clinical Development
- 9.14.4. Clinical Trials Information
- 9.14.5. Safety and Efficacy
- 9.14.6. Product Profile
- 9.15. SAF312: Novartis Pharmaceuticals
- 9.15.1. Product Description
- 9.15.2. Clinical Development
- 9.15.3. Clinical Trials Information
- 9.15.4. Safety and Efficacy
- 9.15.5. Product Profile
- 9.16. OCS-01: Oculis
- 9.16.1. Product Description
- 9.16.2. Other Developmental Activities
- 9.16.3. Clinical Development
- 9.16.4. Clinical Trials Information
- 9.16.5. Safety and Efficacy
- 9.16.6. Product Profile
- 9.17. PRF110: PainReform LTD
- 9.17.1. Product Description
- 9.17.2. Other Developmental Activities
- 9.17.3. Clinical Development
- 9.17.4. Clinical Trials Information
- 9.17.5. Safety and Efficacy
- 9.17.6. Product Profile
- 9.18. Vocacapsaicin (CA-008): Concentric Analgesics
- 9.18.1. Product Description
- 9.18.2. Other Developmental Activities
- 9.18.3. Clinical Development
- 9.18.4. Clinical Trials Information
- 9.18.5. Safety and Efficacy
- 9.18.6. Product Profile
- 9.19. Nepafenac PPDS/Nepafenac Evolute: Mati Therapeutics Inc.
- 9.19.1. Product Description
- 9.19.2. Other Developmental Activities
- 9.19.3. Clinical Development
- 9.19.4. Clinical Trials Information
- 9.19.5. Safety and Efficacy
- 9.19.6. Product Profile
- 10. Postoperative Pain: Seven Major Market Analysis
- 10.1. Key Findings
- 10.2. Methodology of Postoperative Pain Market
- 10.3. Market Size of Postoperative Pain in the 7MM Countries
- 10.4. Market Size of Postoperative Pain by Therapies in the 7MM Countries
- 10.5. Comparison of 7MM Postoperative Pain Market
- 10.6. Discharge Prescription Pattern of Various Analgesic in post-operative Pain among the United States and EU-5
- 10.7. Emerging Drug Analysis
- 10.8. 7MM Market Outlook
- 10.9. United States Market Size
- 10.9.1. Total Market Size of Postoperative Pain in the United States
- 10.9.2. Market Size by Therapies of Postoperative Pain in the United States
- 10.10. EU-5 Market Size
- 10.10.1. Germany
- 10.10.1.1. Total Market size of Postoperative Pain in Germany
- 10.10.1.2. Market Size by Therapies of Postoperative Pain in Germany
- 10.10.2. France
- 10.10.2.1. Total Market size of Postoperative Pain in France
- 10.10.2.2. Market Size of Postoperative Pain by Therapies in France
- 10.10.3. Italy
- 10.10.3.1. Total Market Size of Postoperative Pain in Italy
- 10.10.3.2. Market Size of Postoperative Pain by Therapies in Italy
- 10.10.4. Spain
- 10.10.4.1. Total Market Size of Postoperative Pain in Spain
- 10.10.4.2. Market Size of Postoperative Pain by Therapies in Spain
- 10.10.5. United Kingdom
- 10.10.5.1. Total Market Size of postoperative pain in the United Kingdom
- 10.10.5.2. Market Size of Postoperative Pain by Therapies in the United Kingdom
- 10.11. Japan
- 10.11.1. Total Market Size of Postoperative Pain in Japan
- 10.11.2. Market Size of Postoperative Pain by Therapies in Japan
- 11. KOL Views
- 11.1. US KOL Views
- 11.2. EU5 and Japan KOL Views
- 12. Market Drivers
- 13. Market Barriers
- 14. SWOT Analysis
- 15. Unmet Needs
- 16. Reimbursement and Market Access
- 17. Appendix
- 17.1. Bibliography
- 17.2. Report Methodology
- 18. DelveInsight Capabilities
- 19. Disclaimer
- 20. About DelveInsight
- Table 1: Summary of Postoperative Pain, Market, Epidemiology, and Key Events (2019–2032)
- Table 2: Common Types of Pain (related to acute postoperative pain)
- Table 3: Graded Chronic Pain Scale (GCPS)
- Table 4: Unidimensional Pain Assessment Tools
- Table 5: Multidimensional Pain Assessment Tools
- Table 6: Preoperative Assessment and Patient Education Recommendations
- Table 7: Postoperative Assessment and Patient Education Recommendations
- Table 8: Perioperative Pain Management Considerations and Recommendations
- Table 9: Recommended: Pre- and intra-operative interventions for Inguinal Hernia Repair
- Table 10: Recommended: Pre- and intra-operative interventions for Hallux Valgus Repair Surgery
- Table 11: Recommendations: Pain management after complex spine surgery
- Table 12: Overall recommendations for pain management in patients undergoing elective caesarean section
- Table 13: Total number of Incident cases of Postoperative Pain in the 7MM (2019–2032)
- Table 14: Total number of surgical procedures in the US (2019–2032)
- Table 15: Total number of Incident cases of Postoperative Pain in the US (2019–2032)
- Table 16: Severity-specific incident cases of Postoperative Pain in the US (2019–2032)
- Table 17: Total number of surgical procedures in Germany (2019–2032)
- Table 18: Total number of Incident cases of Postoperative Pain in Germany (2019–2032)
- Table 19: Severity-specific incident cases of Postoperative Pain in Germany (2019–2032)
- Table 20: Total number of surgical procedures in France (2019–2032)
- Table 21: Total number of Incident cases of Postoperative Pain in France (2019–2032)
- Table 22: Severity-specific incident cases of Postoperative Pain in France (2019–2032)
- Table 23: Total number of surgical procedures in Italy (2019–2032)
- Table 24: Total number of Incident cases of Postoperative Pain in Italy (2019–2032)
- Table 25: Severity-specific incident cases of Postoperative Pain in Italy (2019–2032)
- Table 26: Total number of surgical procedures in Spain (2019–2032)
- Table 27: Total number of Incident cases of Postoperative Pain in Spain (2019–2032)
- Table 28: Severity-specific incident cases of Postoperative Pain in Spain (2019–2032)
- Table 29: Total number of surgical procedures in the UK (2019–2032)
- Table 30: Total number of Incident cases of Postoperative Pain in the UK (2019–2032)
- Table 31: Severity-specific incident cases of Postoperative Pain in the UK (2019–2032)
- Table 32: Total number of surgical procedures in Japan (2019–2032)
- Table 33: Total number of Incident cases of Postoperative Pain in Japan (2019–2032)
- Table 34: Severity-specific incident cases of Postoperative Pain in Japan (2019–2032)
- Table 35: Comparison of Marketed Drugs
- Table 36: Dexketoprofen/Tramadol, Clinical Trial Description, 2021
- Table 37: Dsuvia, Clinical Trial Description, 2021
- Table 38: Zalviso, Clinical Trial Description, 2021
- Table 39: Olinvyk, Clinical Trial Description, 2021
- Table 40: Zynrelef (HTX-011), Clinical Trial Description, 2021
- Table 41: XaraColl, Clinical Trial Description, 2021
- Table 42: Posimir (bupivacaine solution), Clinical Trial Description, 2021
- Table 43: Exparel, Clinical Trial Description, 2021
- Table 44: ANJESO (N1539), Clinical Trial Description, 2021
- Table 45: Prolensa (bromfenac ophthalmic solution) 0.07%, Clinical Trial Description, 2021
- Table 46: Dextenza, Clinical Trial Description, 2021
- Table 47: Inveltys, Clinical Trial Description, 2021
- Table 48: Penthrox, Clinical Trial Description, 2021
- Table 49: Maxigesic, Clinical Trial Description, 2021
- Table 50: Comparison of emerging drugs under development (1)
- Table 51: Comparison of emerging drugs under development (2)
- Table 52: Comparison of emerging drugs under development (3)
- Table 53: Comparison of emerging drugs under development (4)
- Table 54: CR845, Clinical Trial Description, 2021
- Table 55: VVZ-149, Clinical Trial Description, 2021
- Table 56: Tramadol, Clinical Trial Description, 2021
- Table 57: F14 (sustained release celecoxib), Clinical Trial Description, 2021
- Table 58: Nefopam hydrochloride 30 mg /Paracetamol 500 mg X2, Clinical Trial Description, 2021
- Table 59: Co-crystal E-58425 (Tramadol/Celecoxib), Clinical Trial Description, 2021
- Table 60: APP13007, Clinical Trial Description, 2021
- Table 61: ACP-044, Clinical Trial Description, 2021
- Table 62: NVK-009, Clinical Trial Description, 2021
- Table 63: TLC590, Clinical Trial Description, 2021
- Table 64: MR-107A-01, Clinical Trial Description, 2021
- Table 65: TPU-006, Clinical Trial Description, 2021
- Table 66: SAF312, Clinical Trial Description, 2021
- Table 67: OCS-01, Clinical Trial Description, 2021
- Table 68: PRF 110, Clinical Trial Description, 2021
- Table 69: Vocacapsaicin (CA-008), Clinical Trial Description, 2021
- Table 70: Nepafenac PPDS, Clinical Trial Description, 2021
- Table 71: Market size of postoperative pain in the 7MM, in USD million (2019–2032)
- Table 72: Market size of postoperative pain by therapies in the 7MM, in USD million (2019–2032)
- Table 73: Market size of postoperative pain in the United States, USD million (2019–2032)
- Table 74: Market size of postoperative pain by therapies in the US, in USD million (2019–2032)
- Table 75: Market size of postoperative pain in Germany, in USD million (2019–2032)
- Table 76: Market size of postoperative pain by therapies in Germany, in USD million (2019–2032)
- Table 77: Market size of postoperative pain in France, in USD million (2019–2032)
- Table 78: Market size of postoperative pain by therapies in France, in USD million (2019–2032)
- Table 79: Market size of postoperative pain in Italy, in USD million (2019–2032)
- Table 80: Market size of postoperative pain by therapies in Italy, in USD million (2019–2032)
- Table 81: Market size of postoperative pain in Spain, in USD million (2019–2032)
- Table 82: Market size of postoperative pain by therapies in Spain, in USD million (2019–2032)
- Table 83: Market Size of postoperative pain in the UK, in USD million (2019–2032)
- Table 84: Market size of postoperative pain by therapies in the UK, in USD million (2019–2032)
- Table 85: Market Size of postoperative pain in Japan, in USD million (2019–2032)
- Table 86: Market size of postoperative pain by therapies in Japan, in USD million (2019–2032)
- Figure 1: Types of Pain
- Figure 2: Four basic components for postoperative pain
- Figure 3: Wong-Baker Faces Pain Rating Scale
- Figure 4: Progression from Acute to Chronic Pain
- Figure 5: Progression from Acute to Chronic Pain
- Figure 6: Afferent Nociceptive Pathway
- Figure 7: Efferent Nociceptive pathway
- Figure 8: Negative effects of postoperative pain on the various organ system
- Figure 9: Efferent Nociceptive pathway
- Figure 10: Present Pain Intensity (PPI)
- Figure 11: Present Pain Intensity (PPI)
- Figure 12: Progression of regional anesthetic applications into formal acute pain medicine programs
- Figure 13: Common techniques for post-operative pain management
- Figure 14: Treatment Algorithm for Acute Postoperative Pain
- Figure 15: Total number of Incident cases of Postoperative Pain in the 7MM (2019–2032)
- Figure 16: Total number of surgical procedures in the US (2019–2032)
- Figure 17: Total number of Incident cases of Postoperative Pain in the US (2019–2032)
- Figure 18: Severity-specific incident cases of Postoperative Pain in the US (2019–2032)
- Figure 19: Total number of surgical procedures in Germany (2019–2032)
- Figure 20: Total number of Incident cases of Postoperative Pain in Germany (2019–2032)
- Figure 21: Severity-specific incident cases of Postoperative Pain in Germany (2019–2032)
- Figure 22: Total number of surgical procedures in France (2019–2032)
- Figure 23: Total number of Incident cases of Postoperative Pain in France (2019–2032)
- Figure 24: Severity-specific incident cases of Postoperative Pain in France (2019–2032)
- Figure 25: Total number of surgical procedures in Italy (2019–2032)
- Figure 26: Total number of Incident cases of Postoperative Pain in Italy (2019–2032)
- Figure 27: Severity-specific incident cases of Postoperative Pain in Italy (2019–2032)
- Figure 28: Total number of surgical procedures in Spain (2019–2032)
- Figure 29: Total number of Incident cases of Postoperative Pain in Spain (2019–2032)
- Figure 30: Severity-specific incident cases of Postoperative Pain in Spain (2019–2032)
- Figure 31: Total number of surgical procedures in the UK (2019–2032)
- Figure 32: Total number of Incident cases of Postoperative Pain in the UK (2019–2032)
- Figure 33: Severity-specific incident cases of Postoperative Pain in the UK (2019–2032)
- Figure 34: Total number of surgical procedures in Japan (2019–2032)
- Figure 35: Total number of Incident cases of Postoperative Pain in Japan (2019–2032)
- Figure 36: Severity-specific incident cases of Postoperative Pain in Japan (2019–2032)
- Figure 37: Patient Journey
- Figure 38: Market size of postoperative pain in the 7MM, in USD million (2019–2032)
- Figure 39: Market size of postoperative pain by therapies in the 7MM, in USD million (2019–2032)
- Figure 40: A representation of intra- and postoperative care considerations
- Figure 41: Market size of postoperative pain in the United States, USD millions (2019–2032)
- Figure 42: Market size of postoperative pain by therapies in the US, in USD million (2019–2032)
- Figure 43: Market size of postoperative pain in Germany, USD million (2019–2032)
- Figure 44: Market size of postoperative pain by therapies in Germany, in USD million (2019–2032)
- Figure 45: Market size of postoperative pain in France, USD million (2019–2032)
- Figure 46: Market size of postoperative pain by therapies in France, in USD million (2019–2032)
- Figure 47: Market size of postoperative pain in Italy, USD million (2019–2032)
- Figure 48: Market size of postoperative pain by therapies in Italy, in USD million (2019–2032)
- Figure 49: Market size of postoperative pain in Spain, USD million (2019–2032)
- Figure 50: Market size of postoperative pain by therapies in Spain, in USD million (2019–2032)
- Figure 51: Market Size of postoperative pain in the UK, USD million (2019–2032)
- Figure 52: Market size of postoperative pain by therapies in the UK, in USD million (2019–2032)
- Figure 53: Market Size of postoperative pain in Japan, USD million (2019–2032)
- Figure 54: Market size of postoperative pain by therapies in Japan, in USD million (2019–2032)
- Figure 55: Market Drivers
- Figure 56: Market Barriers
- Figure 57: SWOT Analysis
- Figure 58: Unmet Needs
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook